Author information
1School of Social Work, Robert Stempel College of Public Health and Social Work, Florida International University, 11200 SW 8th St., AHC5, Miami, FL, 33199, USA. sburke@fiu.edu.
2School of Social Work, Robert Stempel College of Public Health and Social Work, Florida International University, 11200 SW 8th St., AHC5, Miami, FL, 33199, USA.
3Community-Based Research Institute, Florida International University, 11200 SW 8th St. AHC5, Miami, FL, 33199, USA.
4Department of Biostatistics, Robert Stempel College of Public Health and Social Work, Florida International University, 11200 SW 8th St., AHC5, Miami, FL, 33199, USA.
5Department of Dietetics and Nutrition, Robert Stempel College of Public Health and Social Work, Florida International University, 11200 SW 8th St., AHC5, Miami, FL, 33199, USA.
6Florida Atlantic University, Boca Raton, FL, 33431, USA.
Abstract
The impact of APOE on HIV and HCV disease course, cognition, and memory has been understudied in minoritized populations. This study examined whether scores on cognition and depression measures differed by APOE ε4 carrier status while considering HCV and HIV seropositivity and whether these measures were moderated by substance use. A retrospective analysis examined cognitive and psychological data from participants (n = 493) in the Miami Adult Studies on HIV (MASH) cohort. APOE genotyping was performed on banked blood samples. Multiple linear regression was employed to examine differences across participants living with and without HIV and/or HCV and by APOE ε4 genotype. APOE ε4 carriers living with HCV who used cannabis had higher depression scores than non-ε4 carriers, while nonusers had fewer depressive symptoms. APOE ε4 carriers living with HCV had better cognition scores after adjusting for cocaine, opiate, and cannabis use than non-ε4 carriers. Scores on cognitive and depression measures did not differ between APOE ε4 carriers and non-ε4 carriers in participants living with HIV, and substance use did not moderate this relationship. This study was the first of its kind to examine substance use as a moderator for cognition and depression among individuals with HIV and/or HCV stratified by APOE genotype. Findings support further research evaluating the frequency and duration of 1) domains of cognitive functioning impacted by APOE genotype relevant to substance use and 2) the influence of substance use on cognitive and depressive outcomes among adults living with HIV and HCV, HIV, or HCV.